Certara Announces Acquisition of Great Lakes Drug Development, Inc.

August 19, 2013

Company News Release

Acquisition will further increase the depth of Certara?s early drug development analysis, modeling and simulation expertise

Certara

™, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that it has acquired drug development consultancy firm, Great Lakes Drug Development, Inc. (“GLDD”), based in Brighton, MI. Both companies possess considerable expertise in pharmacokinetic (PK) and pharmacodynamic (PD) analysis, project management, and pharmacometric modeling and simulation. GLDD focuses on early development work, while Certara’s products and services span the entire drug development continuum. Financial details about the transaction have not been disclosed.

“This acquisition will enable us to leverage the significant synergies between Certara’s and GLDD’s business focus, experience, and culture, while expanding our customer base,” said Daniel Weiner, Ph.D., senior vice president and general manager at Certara.

The addition of GLDD builds on the capabilities Tripos®, Pharsight® and Simcyp™ bring to Certara.

GLDD’s Chief Executive Officer David Hermann, said, “This is an exciting stage in our company’s evolution. We look forward to joining Certara’s Pharsight Consulting Services to enhance their capabilities and provide our customers with access to additional services and expertise.”

The GLDD office in Brighton, MI will become the sixth in Certara’s worldwide consultancy operations including 75 Ph.D. staff in Sunnyvale, CA; Cary, NC; Montreal, Canada; Tokyo, Japan; and Sheffield, England.